MabGenesis Inc.

¥588.00As of Sun 8 Nov 2026, 12:00 UTC

TSE:653AHealthcare

Country Japan

PE (Fwd) 11.49

TSR 10Y CAGR —

Div yield —

ROE 6.57%

Drug Manufacturers (General)

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap ¥4.736B

ROIC 43.95%

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

¥626

6.41%

(79.19%)

Price above Reference Value

TTM

FYE 31 Mar JPY

FY2025

FY2026

FY2027E

Trend

10Y

Peers

337.5

Revenue¥M

—

144.5

337.5

477.4

133.66%

—

133.66

Revenue growth%

—

133.66

41.42

133.66

—

99.58

Gross margin%

—

98.28

99.58

100.00

98.93

—

10.63

Operating margin%

—

(80.50)

10.63

56.19

(34.93)

—

10.70

Net margin%

—

(71.88)

10.70

51.99

(30.59)

—

P/E ratio (avg)x

—

19.08

—

119.4

EV/EBITx

—

15.97

—

FCF yield (avg)%

—

4.92

—

(9.79)

FCF margin%

—

(126.94)

(9.79)

48.78

(68.37)

—

(0.915)

FCF / Net incomex

—

1.766

(0.915)

0.938

0.426

—

43.95

ROIC%

—

(247.49)

43.95

57.52

(101.77)

—

6.57

Return on equity%

—

(19.51)

6.57

35.85

(6.47)

—

6.18

Return on assets%

—

(18.06)

6.18

29.54

(5.94)

—

EPS¥

—

30.81

—

EPS growth%

—

Bookvalue per sh¥

—

101.36

—

FCF per share¥

—

28.91

—

Dividend per sh¥

—

Div yield (avg)%

—

Payout ratio%

—

8.055

Shares (diluted)M

—

◌8.055

—

Buyback yield%

—

D/E ratiox

—

4.284

Enterprise value¥B

—

4.284

—

LT debt¥M

—

Peers (US$38.31M)

Cap (US$)

Nano Holdings, Inc.

39.31M

—

J-Pharma Co., Ltd.

38.07M

—

TMS Co., Ltd.

37.98M

—

Aldeyra Therapeutics…

38.23M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

—

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

37.47

7.14

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

—

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

—

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics.

Growth vs revenue

Latest

Trend

1Y CAGR

Rel growth

Revenue

¥337.5M

133.66%

1.00×

Cost of revenue

¥1.421M

(42.84%)

0.24×

Operating expenses

¥300.2M

16.26%

0.50×

Asset mix

Trend

Cash and investments

77.29%

Other

22.63%

Goodwill & intangibles

0.08%

Reinvestment returns

No breakdown available